Clinical trials: Gardasil Vaccine
Systemic Lupus Erythematosus
Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women
The purpose of this study is to evaluate the immunogenicity and safety of the HPV vaccine Gardasil in young women.
- Trial name
- NCT00786409
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Chicago
Human Papilloma Virus
Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City
In the genital tract human papilloma virus (HPV), especially types 6 and 11 cause genital warts, the commonest viral sexually transmitted disease.
- Trial name
- NCT02382900
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Systemic Lupus Erythematosus
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Cervical neoplasia is increased in women with SLE most likely due to cervical infection with human papilloma virus (HPV). 70% of cervical cancer is caused by HPV types 16 and 18.
- Trial name
- GARDASIL (NCT01741012)
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Wayne State University
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dose Schedule Study
Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
To demonstrate that Gardasil® vaccine, when given to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months), results in anti-HPV type 16 and anti-HPV type…
- Trial name
- NCT00524745
- Testing
- Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Where
- Vietnam
- Volunteers
- 903 people, healthy volunteers welcome
- Sponsor
- PATH
Anal Intraepithelial Neoplasia, Anal Cancer
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) worldwide. Infection by certain high-risk oncogenic types of HPV (HR-HPV) is the major cause of several cancers in men, notably squamous cell…
- Conditions
- Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus
- Trial name
- NCT03947775
- Testing
- 9-valent HPV vaccination
- Where
- 4 sites in Canada
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) when administered concomitantly or…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02993757
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
- Where
- 5 sites in Malaysia
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Uterine Cervical Cancer
Community Awareness, Resources and Education (CARE II): Project 3
Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix.
- Trial name
- NCT01299714
- Where
- 4 sites in United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center